Ciocci A
Institute of Rheumatology, 1st Chair, University La Sapienza, Rome, Italy.
Curr Med Res Opin. 1989;11(7):471-5. doi: 10.1185/03007998909115934.
An open clinical trial was carried out in 57 patients with osteoarthritis of the knee, hip or spine to assess the effectiveness and tolerability of etodolac. Patients received 200 mg etodolac twice daily for a period of 2 weeks. The results of clinical and patient assessments made at baseline and at the end of the study period showed that there was significant improvement in pain at rest and on active and passive movement, local tenderness, pain on climbing stairs, joint swelling and functional status. No significant changes were seen in clinical severity of the condition or, in patients with osteoarthritis of the knee, in the degree of knee flexion. Patients judged the therapeutic results to be good or excellent more often than the investigator (75% vs 50%). Tolerability of etodolac was very good with few, generally mild side-effects and only 2 patients were withdrawn, more as a precautionary measure than of necessity.
对57例膝、髋或脊柱骨关节炎患者进行了一项开放性临床试验，以评估依托度酸的有效性和耐受性。患者每日两次服用200mg依托度酸，持续2周。在基线和研究期末进行的临床及患者评估结果显示，静息时、主动和被动活动时的疼痛、局部压痛、爬楼梯时的疼痛、关节肿胀及功能状态均有显著改善。病情的临床严重程度未见显著变化，膝骨关节炎患者的膝关节屈曲度也未见显著变化。患者对治疗结果评为良好或优秀的比例高于研究者（75%对50%）。依托度酸的耐受性非常好，副作用很少，且一般较轻，只有2例患者退出试验，更多是作为预防措施而非必要之举。
